Poljak, B., Kova, V., palj, S., & Milisav, I
The specific thresholds that should prompt dose reduction or discontinuation include: ALT or AST elevation exceeding 3 times the patient's baseline value, new or worsening coagulopathy (INR increase of 0.5 or more from baseline), albumin decline below 2.5 g/dL, or new clinical signs of hepatic decompensation such as worsening ascites, encephalopathy, or jaundice [5]
Natural products as a novel therapeutic strategy for NLRP3 inflammasome-mediated gout
Other water volumes can be used when the math is recalculated
Ligament research using rat medial collateral ligament transection models demonstrated that BPC-157 restored biomechanical properties including load tolerance, stiffness, and breaking force to near-normal levels while reducing joint instability